Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer

Background: Dyspnea is a severe symptom of terminal-stage interstitial pneumonia (IP). We commonly use continuous morphine or midazolam for terminal refractory dyspnea. Objective: We aimed to determine whether there is a difference in the use of continuous morphine and midazolam for terminal dyspnea...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabayashi, Hiroko, Kitamura, Hideya, Ikeda, Satoshi, Sekine, Akimasa, Oda, Tsuneyuki, Baba, Tomohisa, Hagiwara, Eri, Sakagami, Takuro, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244508/
https://www.ncbi.nlm.nih.gov/pubmed/34223519
http://dx.doi.org/10.1089/pmr.2021.0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244508/
https://www.ncbi.nlm.nih.gov/pubmed/34223519
http://dx.doi.org/10.1089/pmr.2021.0010

Ejemplares similares